Identification of Key Genes as Potential Drug Targets for Gastric Cancer

doi:10.26599/TST.2022.9010035

	Identification of Key Genes as Potential Drug Targets for Gastric Cancer
	Hossain, Md. Tofazzal 1,2,3; Reza, Md. Selim 1; Peng, Yin 4; Feng, Shengzhong 1; Wei, Yanjie 1
	2023-08-01
发表期刊	TSINGHUA SCIENCE AND TECHNOLOGY
ISSN	1007-0214
卷号	28 期号:4 页码:649-664
摘要	Gastric cancer (GC) is one of the most common cancers and ranks the third in cancer mortality all over the world. The goal of this study was to identify potential hub-genes, highlighting their functions, signaling pathways, and candidate drugs for the treatment of GC patients. We used publicly available next generation sequencing (NGS) data to identify differentially expressed (DE) genes. The top DE genes were mapped to STRING database to construct the protein-protein interaction (PPI) network and top hub genes were selected for further analysis. We found a total of 1555 DE genes with 870 upregulated and 685 downregulated genes in GC. We selected the top 400 (200 upregulated and 200 downregulated) genes to construct a PPI network and extracted the top 15 hub genes. The gene ontology (GO) term and kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses of the 15 hub genes exposed some important functions and signaling pathways that were significantly associated with GC patients. The survival analysis of the hub genes disclosed that the lower expressions of the three hub genes CDH2, COL4A1, and COL5A2 were associated with better survival of GC patients. These three genes might be the candidate biomarkers for the diagnosis and treatment of GC. Then, we considered 3 key proteins (genomic biomarkers) (COL4A1, CDH2, and CO5A2) as the drug target proteins (receptors), performed their docking analysis with the 102 meta-drug agents, and found Everolimus, Docetaxel, Lanreotide, Venetoclax, Temsirolimus, and Nilotinib as the top ranked 6 candidate drugs with respect to our proposed target proteins for the treatment against GC patients. Therefore, the proposed drugs might play vital role for the treatment against GC patients.
关键词	gastric cancer hub genes candidate genes molecular docking candidate drugs
DOI	10.26599/TST.2022.9010035
收录类别	SCI
语种	英语
资助项目	National Key Research and Development Program of China[2018YFB0204403] ; Key Research and Development Project of Guangdong Province[2021B0101310002] ; Strategic Priority CAS Project[XDB38050100] ; National Science Foundation of China[U1813203] ; Shenzhen Basic Research Fund[RCYX2020071411473419] ; Shenzhen Basic Research Fund[KQTD20200820113106007] ; Shenzhen Basic Research Fund[JSGG20201102163800001] ; CAS Key Lab[2011DP173015] ; Youth Innovation Promotion Association[Y2021101]
WOS研究方向	Computer Science ; Engineering
WOS类目	Computer Science, Information Systems ; Computer Science, Software Engineering ; Engineering, Electrical & Electronic
WOS记录号	WOS:000923065700004
出版者	TSINGHUA UNIV PRESS
引用统计	被引频次：3[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://119.78.100.204/handle/2XEOYT63/19933
专题	中国科学院计算技术研究所期刊论文
通讯作者	Wei, Yanjie
作者单位	1.Chinese Acad Sci, Shenzhen Inst Adv Technol, Ctr High Performance Comp, Joint Engn Res Ctr Hlth Big Data Intelligent Anal, Shenzhen 518055, Peoples R China 2.Univ Chinese Acad Sci, Sch Comp Sci & Technol, Beijing 100049, Peoples R China 3.Bangabandhu Sheikh Mujibur Rahman Sci & Technol Un, Dept Stat, Gopalganj 8100, Bangladesh 4.Shenzhen Univ, Dept Pathol, Guangdong Prov Key Lab Genome Stabil & Dis Prevent, Shenzhen 518060, Peoples R China
推荐引用方式 GB/T 7714	Hossain, Md. Tofazzal,Reza, Md. Selim,Peng, Yin,et al. Identification of Key Genes as Potential Drug Targets for Gastric Cancer[J]. TSINGHUA SCIENCE AND TECHNOLOGY,2023,28(4):649-664.
APA	Hossain, Md. Tofazzal,Reza, Md. Selim,Peng, Yin,Feng, Shengzhong,&Wei, Yanjie.(2023).Identification of Key Genes as Potential Drug Targets for Gastric Cancer.TSINGHUA SCIENCE AND TECHNOLOGY,28(4),649-664.
MLA	Hossain, Md. Tofazzal,et al."Identification of Key Genes as Potential Drug Targets for Gastric Cancer".TSINGHUA SCIENCE AND TECHNOLOGY 28.4(2023):649-664.